Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Two studies inScience report that co-deletion of MTAP — which is common in CDKN2A-deleted cancers — is not a silent passenger event but renders cells sensitive to inhibition of protein arginine methyltransferase 5 (PRMT5), a dependency that could be therapeutically targeted in MTAP-deleted cancers.
Enriquez-Navaset al. show that an evolution-based adaptive treatment strategy is more effective than standard therapy for controlling tumour growth in orthotopic xenograft mouse models of breast cancer.
Tumour metastasis is a major contributor to the mortality of cancer patients, so why is this phase of cancer pathogenesis not routinely targeted? This Review discusses the possible strategies — including preclinical research, combination therapies and clinical trial designs — that could be developed to target metastasis.
This Review summarizes immune evasion mechanisms that limit the therapeutic efficacy of cancer vaccines. The authors discuss how improving vaccine design and using vaccines in combination with other anticancer therapies can boost treatment efficacy in patients with established cancers.
This Review discusses technological and biologically based advances in radiotherapy. The authors envisage that these two major strategies will act synergistically to further widen the therapeutic window of radiation oncology in the era of precision medicine.
Using genomic data, this Analysis demonstrates that commonly inherited single nucleotide polymorphisms (SNPs) occurring in genes of the p53 pathway affect the incidence of a broad range of cancers, more so than SNPs in other pathways. This has implications for p53-mediated tumour suppression in humans.
Current cancer therapies exert selective pressures that drive the evolution of drug-resistant clones. In this Opinion article, the authors argue that induction of stable tumour reversion represents an alternative strategy that could reduce resistance and thus effectively and durably treat cancer.